Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Preferred Stock Liabilities (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Preferred Stock Liabilities for 13 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Preferred Stock Liabilities fell 2.89% year-over-year to $1.3 million, compared with a TTM value of $1.3 million through Dec 2025, down 2.89%, and an annual FY2025 reading of $1.3 million, down 2.89% over the prior year.
  • Preferred Stock Liabilities was $1.3 million for Q4 2025 at Enanta Pharmaceuticals, roughly flat from $1.3 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $1.5 million in Q3 2021 and bottomed at $1.3 million in Q3 2025.
  • Average Preferred Stock Liabilities over 5 years is $1.4 million, with a median of $1.4 million recorded in 2022.
  • Peak annual rise in Preferred Stock Liabilities hit 1.83% in 2021, while the deepest fall reached 9.15% in 2021.
  • Year by year, Preferred Stock Liabilities stood at $1.5 million in 2021, then decreased by 5.51% to $1.4 million in 2022, then changed by 0.0% to $1.4 million in 2023, then dropped by 5.13% to $1.3 million in 2024, then fell by 2.89% to $1.3 million in 2025.
  • Business Quant data shows Preferred Stock Liabilities for ENTA at $1.3 million in Q4 2025, $1.3 million in Q3 2025, and $1.3 million in Q2 2025.